A national study of a telephone support service for patients receiving office-based buprenorphine medication-assisted treatment: Study feasibility and sample description

Ruetsch, Charles; Cacciola, John S.; Tkacz, Joseph

doi:10.1016/j.jsat.2010.07.003

Cited by 12 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest RCT (five times the size of the others combined) of fair quality (n=1426) is an industry-sponsored study where patients new to buprenorphine treatment were randomized to receive in-person buprenorphine MAT (TAU) or buprenorphine MAT plus a Here-To-Help (HTH) IT intervention consisting of calls from care coaches and access to online educational materials, treatment calendars, and self-reported information from previous participants. 26,60 At 12 months, ITT analysis indicated no significant difference between groups (55.0% HTH vs. 56.1% TAU, p-value=NR). Planned post-hoc analysis revealed that people who completed a greater number of intervention calls with coaches had a greater probability of retention in MAT (adjusted logistic regression Exp (β)=1.01, p<0.001) and 64 percent of participants in the HTH program who completed at least three HTH sessions remained in buprenorphine MAT compared with 56 percent in TAU (p<0.025).…”

Section: Health Information Technologymentioning

confidence: 87%

“…Seven unique completed studies (three fair-quality RCTs, one poor-quality RCT, and three fair-quality cohort studies), [20][21][22][23][24][25][26]60 met the inclusion criteria for health IT interventions, including an active control involving in-person MAT as a comparator, and MAT retention as an outcome. Table 4 provides a summary of findings across health IT interventions and Appendix B Table 3 provides details for included studies.…”

Section: Health Information Technologymentioning

confidence: 99%

See 1 more Smart Citation

Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review

Chan¹,

Gean²,

Arkhipova-Jenkins³

et al. 2020

View full text Add to dashboard Cite

Aims. American deaths from opioid overdose now approach 50,000 annually. While evidence shows that medications for addiction treatment (MAT) save lives, retaining patients in MAT programs is challenging. The U.S. Agency for Healthcare Research and Quality, on behalf of the U.S. Department of Health and Human Services, commissioned a rapid evidence review on the effectiveness of interventions to promote a broader understanding of the published literature on MAT retention among adults with opioid use disorder (OUD). Methods. We searched MEDLINE and the Cochrane Library from February 12, 2009, through August 20, 2019, for systematic reviews (SRs) and randomized controlled trials (RCTs). We summarized evidence for six retention intervention types: care settings/services/logistical support, contingency management, health information technology (IT), extended-release (XR) medication-based treatment, psychosocial support, and financial support. Our primary outcome was retention, defined as continued medication engagement for at least 3 months after MAT initiation. Secondary outcomes included mortality and harms. Findings. Key findings from 2 SRs and 39 primary studies include: • Most studies of MAT for OUD do not focus on retention as the primary outcome, are small (e.g., one to two trials per intervention), and have design flaws. • Care setting interventions that initiated MAT in soon-to-be-released incarcerated patients improved retention following release. • Contingency management improved retention when combined with antagonist MAT, but not with agonist forms of MAT. Applicability, however, may be limited due to implementation challenges. • Preliminary trials suggest that retention in MAT supported with health IT approaches may be no worse than in-person approaches. • Early studies suggest no difference in retention with XR-buprenorphine in either injectable or implant formulations compared with daily buprenorphine. There were conflicting results with XR-naltrexone injection compared with daily buprenorphine. • The addition of psychosocial interventions did not improve retention; however, many studies included some form of counseling in the control groups, potentially obscuring evidence of effectiveness. Harms were infrequently reported across studies except in studies of XR formulations. Similarly, few studies reported whether participant characteristics influenced retention. Conclusions. While patients who receive longer-term treatment with MAT have improved outcomes, fewer than half of the identified studies measured treatment retention as a primary outcome. Limited evidence suggests criminal justice prerelease MAT initiation and the use of contingency management for patients on antagonist forms of MAT may aid retention. XR viii and daily buprenorphine formulations appear to be equivalent for treatment retention and comparisons of XR-naltrexone versus daily buprenorphine showed conflicting results. Integrating MAT treatment with medical and social services and the use of health IT did not change retention. Some s...

show abstract

Section: Health Information Technologymentioning

confidence: 87%

Section: Health Information Technologymentioning

confidence: 99%

Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review

Chan¹,

Gean²,

Arkhipova-Jenkins³

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A total of 324 SPRSs in 40 states successfully recruited patients into the study. For additional detail regarding study methodology, see Ref. 27.…”

Section: Methodsmentioning

confidence: 99%

“…This study was conducted as part of a larger project examining a new disease management program called HereToHelp™ (HTH), which was designed for opioid‐dependent patients new to buprenorphine 27 . HTH is a confidential, outbound, telephonic support program which was administered by the manufacturer of Suboxone ® and Subutex ® (Reckitt Benckiser Pharmaceuticals Inc., Slough, United Kingdom).…”

Section: Methodsmentioning

confidence: 99%

Compliance with Buprenorphine Medication‐Assisted Treatment and Relapse to Opioid Use

et al. 2011

Self Cite

View full text Add to dashboard Cite

Opioid dependence (OD), often characterized as a chronic relapsing disorder, affects millions of people worldwide. The purpose of this study was to examine the effect of compliance with buprenorphine on reducing relapse among a sample of patients in treatment for OD. Patients new to buprenorphine (N = 703) completed the Addiction Severity Index (ASI) at baseline, and at 1, 2, and 3 months postbaseline. The ASI is a semistructured interview designed to measure problem severity in seven functional areas known to be affected by alcohol and drug dependence. Compliance was defined as taking buprenorphine medication on at least 22 of the past 28 days (80%), while relapse classification was based on resumed use of opioids during the follow-up period (months 2 and 3). Relapse was regressed onto demographic indicators, baseline ASI composite scores, and compliance with buprenorphine. Noncompliant patients were over 10 times more likely to relapse than those who were compliant (exp β= 10.55; p < .001). Neither demographics nor baseline ASI composite scores were predictive of relapse (p's > .05). Compliance with medication-assisted treatment supports abstinence, essential for patient recovery. Understanding the factors that drive treatment compliance and noncompliance may assist providers in supporting patient compliance and recovery.

show abstract

“…Several articles referred to TC as 'low cost'; 31,50,58,61,73,106,119 however, a handful of articles included further information on the cost of TC. 36,74,96,108,110,123 In summary, these articles describe per-participant costs ranging between approximately 100-200 dollars. The detailed cost information from these studies is reported here.…”

Section: Cost Analysismentioning

confidence: 99%

The effectiveness of telephone counselling in the treatment of illicit drug and alcohol use concerns

Gates¹,

Albertella²

2015

J Telemed Telecare

View full text Add to dashboard Cite

show abstract

A national study of a telephone support service for patients receiving office-based buprenorphine medication-assisted treatment: Study feasibility and sample description

Cited by 12 publications

References 35 publications

Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review

Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review

Compliance with Buprenorphine Medication‐Assisted Treatment and Relapse to Opioid Use

The effectiveness of telephone counselling in the treatment of illicit drug and alcohol use concerns

Contact Info

Product

Resources

About